[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ihab Elsayed Hassan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":62},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100619811","phase-2-pentoxifylline-in-patients-with-ulcerative-colitis-100619811",false,"NCT07349472","Pentoxifylline in Patients With Ulcerative Colitis","Clinical Study Evaluating Safety and Efficacy of Pentoxifylline in Patients With Ulcerative Colitis","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Both male and female will be included\n* Negative pregnancy test and effective contraception.\n* Mild and moderate UC patients\n\nExclusion Criteria:\n\n* Breast feeding\n* Significant liver and kidney function abnormalities\n* Diabetic patients\n* Colorectal cancer patients\n* Patients with severe UC\n* Patients taking rectal or systemic steroids\n* Patients taking immunosuppressives or biological therapies\n* Addiction to alcohol and \u002F or drugs\n* Known allergy to the studied medications","ALL","18 Years","70 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Ulcerative colitis (UC) is a persistent, idiopathic form of inflammatory bowel disease (IBD) marked by uninterrupted inflammation of the colon's mucosal lining, usually starting at the rectum and progressing proximally in a continuous manner. It manifests clinically with recurrent episodes of abdominal pain, bloody diarrhea, urgency, tenesmus, and weight loss. The precise cause of UC is still unknown; however, it is thought to arise from a multifactorial interaction involving genetic susceptibility, immune system dysregulation, disturbances in gut microbiota composition, and various environmental factors.",[27],"Inflammatory Bowel Diseases","RECRUITING","2026-04-11",{"date":31,"type":32},"2026-04-15","ACTUAL",{"date":34,"type":32},"2026-01-20",{"date":36,"type":21},"2027-02-20",{"name":38,"class":39},"Ihab Elsayed Hassan","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":40},"100621431","phase-2-etoricoxib-in-patients-with-parkinsonian-disease-100621431","NCT07370532","Etoricoxib in Patients With Parkinsonian Disease","Clinical Study to Evaluate Safety and Efficacy of Etoricoxib in Patients With Parkinson's Disease Treated With Conventional Treatment","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Both male and female will be included.\n* Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.\n\nExclusion Criteria:\n\n* Breast feeding\n* Patients with significant liver and kidney function abnormalities.\n* Alcohol and \u002F or drug abusers.\n* Patients with known allergy to the study medications\n* Pregnant women and women with planned pregnancy.\n* Patients who are currently using other anti-inflammatory drugs.","50 Years",{"count":20,"type":21},[24],"Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).",[53],"Parkinson Disease","2026-04-02",{"date":56,"type":32},"2026-04-08",{"date":58,"type":32},"2026-01-30",{"date":60,"type":21},"2027-11-20",{"name":38,"class":39},""]